Browse HMGA2

Summary
SymbolHMGA2
Namehigh mobility group AT-hook 2
Aliases BABL; LIPO; HMGIC; high-mobility group (nonhistone chromosomal) protein isoform I-C; HMGI-C; STQTL9; High-mo ......
Chromosomal Location12q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus.
Domain PF02178 AT hook motif
Function

Functions as a transcriptional regulator. Functions in cell cycle regulation through CCNA2. Plays an important role in chromosome condensation during the meiotic G2/M transition of spermatocytes. Plays a role in postnatal myogenesis, is involved in satellite cell activation (By similarity).

> Gene Ontology
 
Biological Process GO:0000075 cell cycle checkpoint
GO:0000077 DNA damage checkpoint
GO:0000086 G2/M transition of mitotic cell cycle
GO:0000726 non-recombinational repair
GO:0001501 skeletal system development
GO:0001704 formation of primary germ layer
GO:0001706 endoderm formation
GO:0001707 mesoderm formation
GO:0001837 epithelial to mesenchymal transition
GO:0002062 chondrocyte differentiation
GO:0003131 mesodermal-endodermal cell signaling
GO:0006282 regulation of DNA repair
GO:0006284 base-excision repair
GO:0006302 double-strand break repair
GO:0006303 double-strand break repair via nonhomologous end joining
GO:0006323 DNA packaging
GO:0006333 chromatin assembly or disassembly
GO:0006338 chromatin remodeling
GO:0007050 cell cycle arrest
GO:0007067 mitotic nuclear division
GO:0007093 mitotic cell cycle checkpoint
GO:0007095 mitotic G2 DNA damage checkpoint
GO:0007346 regulation of mitotic cell cycle
GO:0007369 gastrulation
GO:0007492 endoderm development
GO:0007498 mesoderm development
GO:0007568 aging
GO:0007569 cell aging
GO:0009314 response to radiation
GO:0009615 response to virus
GO:0010165 response to X-ray
GO:0010212 response to ionizing radiation
GO:0010389 regulation of G2/M transition of mitotic cell cycle
GO:0010948 negative regulation of cell cycle process
GO:0010972 negative regulation of G2/M transition of mitotic cell cycle
GO:0016570 histone modification
GO:0016572 histone phosphorylation
GO:0018105 peptidyl-serine phosphorylation
GO:0018209 peptidyl-serine modification
GO:0019058 viral life cycle
GO:0019079 viral genome replication
GO:0019080 viral gene expression
GO:0019083 viral transcription
GO:0019827 stem cell population maintenance
GO:0030261 chromosome condensation
GO:0031049 programmed DNA elimination
GO:0031052 chromosome breakage
GO:0031497 chromatin assembly
GO:0031507 heterochromatin assembly
GO:0031570 DNA integrity checkpoint
GO:0031572 G2 DNA damage checkpoint
GO:0032897 negative regulation of viral transcription
GO:0035404 histone-serine phosphorylation
GO:0035690 cellular response to drug
GO:0035821 modification of morphology or physiology of other organism
GO:0035978 histone H2A-S139 phosphorylation
GO:0035986 senescence-associated heterochromatin focus assembly
GO:0035987 endodermal cell differentiation
GO:0035988 chondrocyte proliferation
GO:0039692 single stranded viral RNA replication via double stranded DNA intermediate
GO:0039694 viral RNA genome replication
GO:0039703 RNA replication
GO:0042493 response to drug
GO:0042769 DNA damage response, detection of DNA damage
GO:0043388 positive regulation of DNA binding
GO:0043392 negative regulation of DNA binding
GO:0043900 regulation of multi-organism process
GO:0043901 negative regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0043921 modulation by host of viral transcription
GO:0043922 negative regulation by host of viral transcription
GO:0044033 multi-organism metabolic process
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044773 mitotic DNA damage checkpoint
GO:0044774 mitotic DNA integrity checkpoint
GO:0044818 mitotic G2/M transition checkpoint
GO:0044839 cell cycle G2/M phase transition
GO:0045069 regulation of viral genome replication
GO:0045071 negative regulation of viral genome replication
GO:0045091 regulation of single stranded viral RNA replication via double stranded DNA intermediate
GO:0045444 fat cell differentiation
GO:0045738 negative regulation of DNA repair
GO:0045786 negative regulation of cell cycle
GO:0045787 positive regulation of cell cycle
GO:0045869 negative regulation of single stranded viral RNA replication via double stranded DNA intermediate
GO:0045930 negative regulation of mitotic cell cycle
GO:0046782 regulation of viral transcription
GO:0048332 mesoderm morphogenesis
GO:0048333 mesodermal cell differentiation
GO:0048525 negative regulation of viral process
GO:0048762 mesenchymal cell differentiation
GO:0048863 stem cell differentiation
GO:0050792 regulation of viral process
GO:0051052 regulation of DNA metabolic process
GO:0051053 negative regulation of DNA metabolic process
GO:0051098 regulation of binding
GO:0051099 positive regulation of binding
GO:0051100 negative regulation of binding
GO:0051101 regulation of DNA binding
GO:0051216 cartilage development
GO:0051702 interaction with symbiont
GO:0051817 modification of morphology or physiology of other organism involved in symbiotic interaction
GO:0051851 modification by host of symbiont morphology or physiology
GO:0052312 modulation of transcription in other organism involved in symbiotic interaction
GO:0052472 modulation by host of symbiont transcription
GO:0060485 mesenchyme development
GO:0061448 connective tissue development
GO:0070828 heterochromatin organization
GO:0071103 DNA conformation change
GO:0071156 regulation of cell cycle arrest
GO:0071158 positive regulation of cell cycle arrest
GO:0071214 cellular response to abiotic stimulus
GO:0071478 cellular response to radiation
GO:0071479 cellular response to ionizing radiation
GO:0071481 cellular response to X-ray
GO:0072089 stem cell proliferation
GO:0072091 regulation of stem cell proliferation
GO:0090068 positive regulation of cell cycle process
GO:0090342 regulation of cell aging
GO:0090343 positive regulation of cell aging
GO:0090398 cellular senescence
GO:0090402 oncogene-induced cell senescence
GO:0098727 maintenance of cell number
GO:1901987 regulation of cell cycle phase transition
GO:1901988 negative regulation of cell cycle phase transition
GO:1901990 regulation of mitotic cell cycle phase transition
GO:1901991 negative regulation of mitotic cell cycle phase transition
GO:1902749 regulation of cell cycle G2/M phase transition
GO:1902750 negative regulation of cell cycle G2/M phase transition
GO:1903900 regulation of viral life cycle
GO:1903901 negative regulation of viral life cycle
GO:1990164 histone H2A phosphorylation
GO:2000036 regulation of stem cell population maintenance
GO:2000648 positive regulation of stem cell proliferation
GO:2000677 regulation of transcription regulatory region DNA binding
GO:2000679 positive regulation of transcription regulatory region DNA binding
GO:2000683 regulation of cellular response to X-ray
GO:2000685 positive regulation of cellular response to X-ray
GO:2000772 regulation of cellular senescence
GO:2000774 positive regulation of cellular senescence
GO:2000779 regulation of double-strand break repair
GO:2000780 negative regulation of double-strand break repair
GO:2001020 regulation of response to DNA damage stimulus
GO:2001021 negative regulation of response to DNA damage stimulus
GO:2001022 positive regulation of response to DNA damage stimulus
GO:2001023 regulation of response to drug
GO:2001032 regulation of double-strand break repair via nonhomologous end joining
GO:2001033 negative regulation of double-strand break repair via nonhomologous end joining
GO:2001038 regulation of cellular response to drug
Molecular Function GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001047 core promoter binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001078 transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001227 transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003680 AT DNA binding
GO:0003682 chromatin binding
GO:0003906 DNA-(apurinic or apyrimidinic site) lyase activity
GO:0004518 nuclease activity
GO:0004519 endonuclease activity
GO:0004520 endodeoxyribonuclease activity
GO:0004536 deoxyribonuclease activity
GO:0004674 protein serine/threonine kinase activity
GO:0004677 DNA-dependent protein kinase activity
GO:0008134 transcription factor binding
GO:0008301 DNA binding, bending
GO:0016829 lyase activity
GO:0016835 carbon-oxygen lyase activity
GO:0031490 chromatin DNA binding
GO:0031491 nucleosome binding
GO:0031492 nucleosomal DNA binding
GO:0035497 cAMP response element binding
GO:0035500 MH2 domain binding
GO:0035501 MH1 domain binding
GO:0043566 structure-specific DNA binding
GO:0046332 SMAD binding
GO:0051575 5'-deoxyribose-5-phosphate lyase activity
GO:0070742 C2H2 zinc finger domain binding
Cellular Component GO:0000785 chromatin
GO:0000792 heterochromatin
GO:0032993 protein-DNA complex
GO:0035985 senescence-associated heterochromatin focus
GO:0071141 SMAD protein complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-2559583: Cellular Senescence
R-HSA-2262752: Cellular responses to stress
R-HSA-2559586: DNA Damage/Telomere Stress Induced Senescence
R-HSA-2559584: Formation of Senescence-Associated Heterochromatin Foci (SAHF)
Summary
SymbolHMGA2
Namehigh mobility group AT-hook 2
Aliases BABL; LIPO; HMGIC; high-mobility group (nonhistone chromosomal) protein isoform I-C; HMGI-C; STQTL9; High-mo ......
Chromosomal Location12q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between HMGA2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolHMGA2
Namehigh mobility group AT-hook 2
Aliases BABL; LIPO; HMGIC; high-mobility group (nonhistone chromosomal) protein isoform I-C; HMGI-C; STQTL9; High-mo ......
Chromosomal Location12q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of HMGA2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolHMGA2
Namehigh mobility group AT-hook 2
Aliases BABL; LIPO; HMGIC; high-mobility group (nonhistone chromosomal) protein isoform I-C; HMGI-C; STQTL9; High-mo ......
Chromosomal Location12q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of HMGA2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4390.563
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.4620.788
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4240.76
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0580.931
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.0970.451
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.2480.505
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.5940.573
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-2.0930.244
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.530.34
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0550.944
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.140.894
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-1.4630.00107
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of HMGA2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolHMGA2
Namehigh mobility group AT-hook 2
Aliases BABL; LIPO; HMGIC; high-mobility group (nonhistone chromosomal) protein isoform I-C; HMGI-C; STQTL9; High-mo ......
Chromosomal Location12q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HMGA2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolHMGA2
Namehigh mobility group AT-hook 2
Aliases BABL; LIPO; HMGIC; high-mobility group (nonhistone chromosomal) protein isoform I-C; HMGI-C; STQTL9; High-mo ......
Chromosomal Location12q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HMGA2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HMGA2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolHMGA2
Namehigh mobility group AT-hook 2
Aliases BABL; LIPO; HMGIC; high-mobility group (nonhistone chromosomal) protein isoform I-C; HMGI-C; STQTL9; High-mo ......
Chromosomal Location12q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HMGA2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolHMGA2
Namehigh mobility group AT-hook 2
Aliases BABL; LIPO; HMGIC; high-mobility group (nonhistone chromosomal) protein isoform I-C; HMGI-C; STQTL9; High-mo ......
Chromosomal Location12q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of HMGA2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolHMGA2
Namehigh mobility group AT-hook 2
Aliases BABL; LIPO; HMGIC; high-mobility group (nonhistone chromosomal) protein isoform I-C; HMGI-C; STQTL9; High-mo ......
Chromosomal Location12q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between HMGA2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolHMGA2
Namehigh mobility group AT-hook 2
Aliases BABL; LIPO; HMGIC; high-mobility group (nonhistone chromosomal) protein isoform I-C; HMGI-C; STQTL9; High-mo ......
Chromosomal Location12q15
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting HMGA2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.